Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885018 | 1.00 | NUDT1 (0.55) | NUDT1KDM4EL3MBTL1PIK3CDPIK3CB | |
| SCHEMBL179450 | 0.84 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1PIK3CDPIK3CB | |
| SCHEMBL179422 | 0.84 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1TLR8 | |
| SCHEMBL179465 | 0.84 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1PIK3CDPIK3CB | |
| SCHEMBL179496 | 0.84 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1PIK3CDPIK3CB | |
| SCHEMBL179460 | 0.84 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1TLR8 | |
| SCHEMBL179474 | 0.84 | BCL6 (0.43) | NUDT1KDM4EL3MBTL1TLR8 | |
| SCHEMBL179498 | 0.81 | NUDT1 (0.41) | NUDT1KDM4EL3MBTL1 | |
| SCHEMBL179470 | 0.81 | NUDT1 (0.41) | NUDT1KDM4EL3MBTL1 | |
| SCHEMBL16015108 | 0.81 | NUDT1 (0.41) | NUDT1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193182-B2 | Substituted isoquinolin-1(2H)-ones, and methods of use thereof | INTELLIKINE, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | NUDT1 791/4885KDM4E 4349/4885L3MBTL1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.